Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus
Surender Khurana, Lisa R. King, Jody Manischewitz, Olivia Posadas, Ashish Mishra, Dongxiao Liu, John H. Beigel, Rino Rappuoli, John S. Tsang, Hana Golding
Topics & Concepts
Influenza A virus subtype H5N1VirologyAntibodyHighly pathogenicCladeInfluenza A virusVirusNeutralizing antibodyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pandemic2019-20 coronavirus outbreakBiologyMedicineImmunologyGeneOutbreakGeneticsInfectious disease (medical specialty)DiseasePathologyPhylogenetic treeInfluenza Virus Research StudiesImmunotherapy and Immune ResponsesRespiratory viral infections research